Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

被引：0
|
作者：
Jiwon Oh
Paul W. O’Connor
机构：
[1] Johns Hopkins University,Department of Neurology
[2] University of Toronto,St. Michael’s Hospital, Division of Neurology, Department of Medicine
来源：
CNS Drugs | 2013年 / 27卷
关键词：
Multiple Sclerosis; Multiple Sclerosis Patient; Progressive Multifocal Leukoencephalopathy; Natalizumab; Glatiramer Acetate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral disease-modifying agents (DMAs) has significantly changed the landscape of therapeutic options for MS patients. Many of these oral DMAs have demonstrated satisfactory safety and tolerability profiles in clinical trial settings, but the long-term safety of these agents is an important concern. This review discusses salient points on the safety and clinical efficacy of the approved and emerging novel oral therapies in RRMS, including fingolimod, teriflunomide, dimethyl fumarate, laquinimod, and cladribine.
引用
收藏
页码：591 / 609
页数：18
相关论文
共 50 条
  • [1] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CNS DRUGS, 2013, 27 (08) : 591 - 609
  • [2] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Paolicelli, Damiano
    Manni, Alessia
    Iaffaldano, Antonio
    Trojano, Maria
    CNS DRUGS, 2020, 34 (01) : 65 - 92
  • [3] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Damiano Paolicelli
    Alessia Manni
    Antonio Iaffaldano
    Maria Trojano
    CNS Drugs, 2020, 34 : 65 - 92
  • [4] Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
    Gajofatto, Alberto
    Turatti, Marco
    Monaco, Salvatore
    Benedetti, Maria Donata
    DRUG HEALTHCARE AND PATIENT SAFETY, 2015, 7 : 157 - 167
  • [5] The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
    Shahtaheri, Rahil Sadat
    Nikfar, Shekoufeh
    Khorasani, Elahe
    Sabbagh-Baniazad, Mansoureh
    Goudarzi, Zahra
    Emamikhah, Maziar
    CURRENT JOURNAL OF NEUROLOGY, 2020, 19 (03): : 138 - 145
  • [6] Oral therapies for treatment of relapsing-remitting multiple sclerosis in austria
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Kraus, J.
    Kalcher, S.
    Kvas, E.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 179 - 179
  • [7] Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis
    Guarnera, Cristina
    Bramanti, Placido
    Mazzon, Emanuela
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2193 - 2207
  • [8] Safety and tolerability of Copaxone® in paediatric patients with relapsing-remitting multiple sclerosis
    Krupp, L
    Banwell, BL
    Picone, M
    Dunn, J
    Weinstock-Guttman, B
    Pardo, L
    MULTIPLE SCLEROSIS JOURNAL, 2005, 11 : S85 - S85
  • [9] Long-Term Efficacy, Safety and Tolerability of Ponesimod in Patients with Relapsing-Remitting Multiple Sclerosis
    Freedman, Mark
    Boster, Aaron
    Fernandez, Oscar
    Melanson, Maria
    Pozzilli, Carlo
    D'Ambrosio, Daniele
    Sidorenko, Tatiana
    Olsson, Tomas
    NEUROLOGY, 2013, 80
  • [10] Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
    Marriott, James J.
    O'Connor, Paul W.
    REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) : 179 - 188
12345